QNRXQuoin Pharmaceuticals, Ltd.
- GlobeNewswire
Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton Syndrome
Kristi and Kodi Share Their Experience Living with the Rare Genetic Skin Disease, Alongside Insights from Pediatric Dermatologist Moise Levy, MD Kodi, who lives with Netherton Syndrome, in the latest NETHERTON NOW ...
- GlobeNewswire
Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results
– Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome; Primary and Key Secondary Endpoints Achieved Statistical Significance Versus Pre-Specified Alpha-Adjusted Target –Announces ...
- GlobeNewswire
Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026
ASHBURN, Va., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
- GlobeNewswire
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient’s Skin Improved ...
- Analyst Upgrades
Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18
Canaccord Genuity analyst Whitney Ijem initiates coverage on Quoin Pharmaceuticals with a Buy rating and announces Price Target of $18. ...
- GlobeNewswire
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
– Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug designation milestone provides 10 years of market exclusivity for Peeling Skin Syndrome in Europe ...
- Analyst Upgrades
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Analysts initiated coverage on ASBH, QNRX, AXGN and HOOD with bullish ratings and targets; IDXX received a Sector Weight rating. ...
- Analyst Upgrades
BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14
BTIG analyst Jeet Mukherjee initiates coverage on Quoin Pharmaceuticals with a Buy rating and announces Price Target of $14. ...
- Analyst Upgrades
Lake Street Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Lake Street analyst Thomas Flaten initiates coverage on Quoin Pharmaceuticals with a Buy rating and announces Price Target of $20. ...
- GlobeNewswire
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
ASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
- GlobeNewswire
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin ...
- GlobeNewswire
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
Second Rare Pediatric Disease (RPD) Designation for QRX003FDA Previously Granted RPD Designation for QRX003 in Netherton SyndromeIf a New Drug Application (NDA) for QRX003 Is Approved for Peeling Skin Syndrome, Quoin ...
- GlobeNewswire
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
- GlobeNewswire
Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
Interim Analysis of the First Six Patients to Complete 12 Weeks of Treatment Met Pre-Specified Alpha Adjusted Target for Primary Endpoint with Statistical Significance Four of Six (66.7%) Participants Achieved the ...
- GlobeNewswire
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
– Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – ...
- GlobeNewswire
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
- GlobeNewswire
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and EuropeFDA Expressed No Safety Concerns Over Study Design and Duration of DosingFirst-Ever Formal ...
- GlobeNewswire
Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome
ASHBURN, Va., June 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan ...
- GlobeNewswire
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDAPivotal Phase 3 Study Expected to Initiate in the Second Half ...
- GlobeNewswire
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
Supports Quoin's planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan's MHLW ASHBURN, Va., June 18, 2026 ...
- GlobeNewswire
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program
Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved' or ‘Significantly Improved' from Baseline Assessment Across Key Clinical Endpoints All Six Patients Are Younger than 10 ...
- GlobeNewswire
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation, and Fast Track ...
- GlobeNewswire
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome
-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data from Investigator-led ...
- GlobeNewswire
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW Confirmed QRX003 ...
- Analyst Upgrades
LUCID CAPITAL MARKETS Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $30
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Quoin Pharmaceuticals with a Buy rating and announces Price Target of $30. ...